Foundation will bring together hundreds of caregivers researchers, healthcare providers, clinical trialists, scientists, advocacy group members, and industry partners for the Foundation's third ...

Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce exciting new data from its Phase 1b clinical trial evaluating azer-cel (azercabtagene zapreleucel) in ...

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial ...

Your personal privacy depends on your awareness, tech controls that allow you to decide what to share, and public policies that take personal privacy into account.

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

Filipp Egorov started his career in public relations. He saw an opportunity for a pivot when the COVID-19 pandemic hit and ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the ...

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain ...

“The data presented at ASCO strengthen our conviction that ziftomenib has potential to become a meaningful treatment option for patients with relapsed or refractory AML with NPM1 mutations — patients ...

Content-driven healthcare professional (HCP) engagement more than doubles treatment adoption. Despite proven effectiveness, there is a disconnect between creation and field execution, suggesting a ...

Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis ...